ANI Pharmaceuticals — Third Quarter 2026 Earnings Summary

ANI Pharmaceuticals reported third-quarter 2026 net revenues of $290.8 million, representing a 27.6% year-over-year increase driven by strong performance in its Rare Disease and Generics segments. The company achieved a diluted GAAP income per share of $1.51 and adjusted non-GAAP diluted earnings per share of $2.70, while announcing a recommended public offer to acquire Egetis Therapeutics for approximately $560 million. Management narrowed its full-year 2026 total revenue guidance to $1,085–$1,125 million and raised adjusted non-GAAP EBITDA guidance to $290–$300 million. Additionally, the company repurchased $20 million in common stock year-to-date and highlighted continued growth momentum for its Cortrophin Gel product line.